---
layout: post
title: "Determination That NYMALIZE (nimodipine), Oral Solution, 3 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-05 19:08:28 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-03083
original_published: 2021-02-17 00:00:00 +0000
significance: 8.00
---

# Determination That NYMALIZE (nimodipine), Oral Solution, 3 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** February 17, 2021 00:00 UTC
**Document Number:** 2021-03083

## Summary

The Food and Drug Administration (FDA, the Agency, or we) has determined that NYMALIZE (nimodipine), oral solution, 3 milligrams (mg)/milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for nimodipine, oral solution, 3 mg/mL, if all other legal and regulatory requirements are met.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/02/17/2021-03083/determination-that-nymalize-nimodipine-oral-solution-3-milligramsmilliliter-was-not-withdrawn-from)
- API: https://www.federalregister.gov/api/v1/documents/2021-03083

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
